11/13/2026
A closer look at the INSPIRE that led to tildrakizumab-asmn's (Ilumya) expanded approval for the treatment of adults with psoriatic .
Today, we're taking a look at the pair of INSPIRE trials that led to tildrakizumab-asmn's (Ilumya) expanded approval for the treatment of adults with psoriatic arthritis.